Masuhr F, Mehraein S
Department of Neurology, Charité Medical School, Humboldt-Universität, Berlin, Germany.
Neurocrit Care. 2004;1(3):355-61. doi: 10.1385/ncc:1:3:355.
Although anticoagulation (AC) reduces the risk of a fatal outcome or severe disability in patients with cerebral venous and sinus thrombosis (CVST), prognosis of severe cases is still difficult to predict. The authors studied the clinical course of patients with CVST who died despite AC therapy to look for clinical features that might explain the lethal course of these patients.
Retrospective analysis of a series of 79 consecutive patients with CVST who were treated with a standard regimen of dose-adjusted iv heparin. Case histories of patients with a fatal outcome are presented.
The authors identified eight patients with a fatal outcome. All patients were stuporous or comatose at the start of AC, and four patients showed markedly delayed intracranial circulation times, indicating extensive venous thrombosis. Two patients improved, but deteriorated secondarily after reduction or discontinuation of AC. Sufficient activated partial thromboplastin time levels were reached only after a delay in three patients, and critical deterioration occurred in two of them during this time.
Although inadequate AC may have contributed to the fatal outcome, some patients with extensive venous thrombosis who are stuporous or comatose at the start of AC may carry an increased risk of death, despite heparin therapy. More aggressive treatment approaches, such as endovascular thrombolysis, may be needed for this subgroup of patients with CVST.
尽管抗凝治疗(AC)可降低脑静脉窦血栓形成(CVST)患者发生致命后果或严重残疾的风险,但重症病例的预后仍难以预测。作者研究了尽管接受了AC治疗仍死亡的CVST患者的临床病程,以寻找可能解释这些患者致命病程的临床特征。
对79例连续接受剂量调整静脉肝素标准方案治疗的CVST患者进行回顾性分析。呈现了有致命结局患者的病历。
作者确定了8例有致命结局的患者。所有患者在开始AC治疗时均处于昏睡或昏迷状态,4例患者颅内循环时间明显延迟,表明存在广泛的静脉血栓形成。2例患者病情改善,但在AC剂量减少或停用后病情继发恶化。仅3例患者在延迟后达到足够的活化部分凝血活酶时间水平,其中2例在此期间发生严重恶化。
尽管AC不足可能导致了致命结局,但一些在开始AC治疗时处于昏睡或昏迷状态且有广泛静脉血栓形成的患者,尽管接受了肝素治疗,死亡风险可能仍会增加。对于这一亚组的CVST患者,可能需要更积极的治疗方法,如血管内溶栓。